Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

Treatment outcomes in patients with newly diagnosed multiple myeloma receiving ixazomib as initial therapy: A retrospective, observational, real-world historical database analysis from China

View Full Paper
Ask AI
Bookmark
Share

Authors

GAGang AnWYWenqiang YanSDShuhui Deng

Discussion

Loading...

Member takes

Overview

Retrospective analysis finds ixazomib effective with 82% response rate in transplant-ineligible multiple myeloma patients.

Key Points

  • To evaluate the efficacy and safety of ixazomib-based regimens in treating transplant-ineligible NDMM patients in China.
  • Retrospective database analysis of MM patients from the NICHE-MM registry in China.
  • Included patients aged 18+ years with confirmed NDMM treated with ixazomib.
  • Primary objectives included assessing treatment patterns and time-to-event outcomes.
  • Total of 431 patients analyzed; 146 received ixazomib-based regimens.
  • Overall response rate of 82%, with 51% achieving very good partial response or better.
  • Median progression-free survival was 24.2 months with 12-month PFS rate of 81%.
  • Adverse events were manageable with 76% of patients maintaining a 4 mg dose of ixazomib.

Cite This Study

An et al. (2025) studied this question.

synapsesocial.com/papers/693624d74fa91c937236d0b8https://doi.org/10.1182/blood-2025-2246
View Full Paper
Ask AI
Bookmark
Share